Long- and short-acting inhaled beta2-agonists: Do benefit-risk-ratios differ in the treatment of bronchial asthma and COPD?

Machine translation Machine translation
作者 Richter, B
类别 Broad synthesis
期刊Zeitschrift für Allgemeinmedizin
Year 2006
連結 DOI

此文書包括 13 Systematic reviews Systematic reviews (13 references)

Loading references information
背景/目的：吸入β2-激动剂使用了几十年，实现支气管扩张和减轻支气管哮喘和慢性阻塞性肺病的症状。尽管有无数的随机对照试验（RCT）的效益 - 风险比仍然有待解决。方法：由于公布的信息有关文件的丰度的系统评价和荟萃分析手段进行了评价。为此目的，Cochrane图书馆和MEDLINE中进行一个简单的搜索。结果：超过250项随机对照试验研究的疗效和β2-受体激动剂吸入治疗可能存在的风险的各个方面。尽管相较于安慰剂的临床优势被注意到，与吸入糖皮质激素直接比较不能证明作为衡量例如，通过恶化率相关的优势，如果要对比仅β2-受体激动剂治疗。在另一方面，联合治疗格外有长效β2-受体激动剂和吸入糖皮质激素占了改善哮喘和部分慢性阻塞性肺病呼吸困难加重。有关β2-受体激动剂治疗的安全考虑数据仍然不足，尽管随机对照试验的大量 - 最显着的长期调查失踪。这其中包括评估死亡率呈现不一致的结果，由于过早的终止试验的唯一RCT。毫无疑问，这些成果在未来的试验加以澄清。结论：唯一的β2-受体激动剂治疗的效益风险比仍然悬而未决。当用吸入糖皮质激素联合上有替代指标产生积极的影响。对病人有关结果这样的治疗和阻塞性气道疾病的过程中的长期效果需要进一步的科学解释。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 2c4ef351a948acd23b8f0469bb35478bc816f204
First added on: Jun 19, 2013
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: Deutsch

If you prefer to see the machine translation we assume you accept our terms of use

Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: Deutsch, English

If you prefer to see the machine translation we assume you accept our terms of use